Gastroresistant pharmaceutical formulations for oral administration containing salts of bile acids
First Claim
1. A pharmaceutical formulation for oral use consisting of a core and an outer coating, said core containing a salt of a bile acid, said bile acid being a member selected from the group consisting of cholic, deoxycholic, chenodeoxycholic, iocholic, iodeoxycholic and ursodeoxycholic acids, said bile acid salt being a member selected from the group consisting of the salt with sodium, lithium, potassium, triethylamine, triethanolamine, trimethanolamine, N-methylmorpholine, 1-(2-hydroxyethyl)-pyrrolidine, L-arginine, L-lysine, L-ornithine, D-glucamine, N-methyl-D-glucamine, glucosamine and choline, the amount of said bile acid salt being 158-582 mgs, said outer coating is insoluble in the acidic gastric juice but is soluble at a pH higher than 5, said formulation containing between said core and said outer coating a non-protective coating in the amount of 1-5% by weight with respect to said non-coated portion, said non-protective coating consisting of hydroxypropylmethylcellulose, polyethylene glycol 6000, titanium dioxide and talc.
1 Assignment
0 Petitions
Accused Products
Abstract
Pharmaceutical formulations for oral administration coated by an enterosoluble gastroresistant film, preferably selected from gastroresistant granulates, gastroresistant tablets, gastroresistant hard gelatine capsules containing powders or granulates or two or more tablets or oily suspensions, gastroresistant soft gelatine capsules containing oily suspensions and hard gelatine capsules containing gastroresistant granulates or two or more gastroresistant tablets, containing therapeutically effective amounts of salts of bile acids with alkali metals or organic bases, process for their preparation and therapeutic use thereof in the treatment of biliary calculoses, biliary dyspepsias, biliary cirrhosis and chronic and cholestatic hepatopathies.
73 Citations
5 Claims
- 1. A pharmaceutical formulation for oral use consisting of a core and an outer coating, said core containing a salt of a bile acid, said bile acid being a member selected from the group consisting of cholic, deoxycholic, chenodeoxycholic, iocholic, iodeoxycholic and ursodeoxycholic acids, said bile acid salt being a member selected from the group consisting of the salt with sodium, lithium, potassium, triethylamine, triethanolamine, trimethanolamine, N-methylmorpholine, 1-(2-hydroxyethyl)-pyrrolidine, L-arginine, L-lysine, L-ornithine, D-glucamine, N-methyl-D-glucamine, glucosamine and choline, the amount of said bile acid salt being 158-582 mgs, said outer coating is insoluble in the acidic gastric juice but is soluble at a pH higher than 5, said formulation containing between said core and said outer coating a non-protective coating in the amount of 1-5% by weight with respect to said non-coated portion, said non-protective coating consisting of hydroxypropylmethylcellulose, polyethylene glycol 6000, titanium dioxide and talc.
-
3. A pharmaceutical formulation for oral use consisting of a core and an outer coating said core containing a salt of a bile acid, said bile acid being a member selected from the group consisting of cholic, deoxycholic, chenodeoxycholic, iocholic, iodeoxycholic and ursodeoxycholic acids, said bile acid salt being a member selected from the group consisting of the salt with sodium, lithium, potassium, triethylamine, triethanolamine, trimethanolamine, N-methylmorpholine, 1-(2-hydroxyethyl)-pyrrolidine, L-arginine, L-lysine, L-ornithine, D-glucamine, N-methyl-D-glucamine, glucosamine and choline, the amount of said bile acid salt being 158-582 mgs, said outer coating is insoluble in the acidic gastric juice but is soluble at a pH higher than 5, said formulation containing between said core and said outer coating a non-protective coating in the amount of 1-5% by weight with respect to said non-coated portion, said non-protective coating consisting of at least one member selected from the group consisting of hydroxypropylmethyl-cellulose, polyethylene glycol 6000, titanium dioxide and talc wherein said non-protective coating additionally contains a pharmaceutically acceptable dye.
-
5. The method of treatment of a living subject affected by biliary calculoses, biliary dyspepsias, biliary cirrhosis, chronic and cholestatic hepatopaties, which consists of orally administering to said subject a formulation for oral use consisting of a core and an outer coating, said core containing a bile acid salt, said bile acid being a member selected from the group consisting of cholic, deoxycholic, chenodeoxycholic, iocholic, iodexycholic and ursodeoxycholic acids and mixtures thereof, said salt of said bile acid being with an alkali metal or an organic base, the amount of said bile acid salt being 158-582 mgs and said outer coating is insoluble in the acidic gastric juice but is soluble at a pH higher than 5, said formulation having a non-protective coating between said core and said outer coating.
Specification